Daniel L. Alkon - 16 Dec 2022 Form 4 Insider Report for Synaptogenix, Inc. (SNPX)

Reporting relationship: President and CSO, Director
Issuer ticker: SNPX
Reported as of: 16 Dec 2022
Net transaction value: -$23,072
SEC form: 4
Accepted by SEC: 20 Dec 2022, 19:01:10 UTC
Prior SEC filing: 01 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ Robert Weinstein, Attorney-in-fact

Key filing fact

Daniel L. Alkon filed Form 4 for Synaptogenix, Inc. (SNPX) on 20 Dec 2022.

Key facts

This page summarizes Daniel L. Alkon's Form 4 filing for Synaptogenix, Inc. (SNPX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Dec 2022, 19:01.

Change

Previous filing in this sequence was filed on 01 Dec 2022.
Current net transaction value: -$23,072.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNPX transaction

Common Stock, par value $0.0001 per share

Sale

Transaction value: $23,072
Shares: -19,688
Change %: -36%
Price: $1.17
Shares after: 35,546
Date: 16 Dec 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.